Idiopathic Pulmonary Fibrosis Treatment Market Scope And Analysis

Idiopathic Pulmonary Fibrosis Treatment Market Report Scope

Recent Developments: 

Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the idiopathic pulmonary fibrosis treatment market. A few recent developments are listed below:   

• In May 2023, Boehringer Ingelheim initiated the clinical development of BI 765423, a breakthrough IL-11 inhibitor antibody. The Phase 1 study (NCT05658107) focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteer subjects. Preclinical studies have shown promising results of this anti-IL-11 drug in inhibiting and potentially reversing fibrosis in various fibrotic cases.
• In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550. BI 1015550 is an experimental phosphodiesterase 4B (PDE4B) inhibitor discovered for treating individuals suffering from idiopathic pulmonary fibrosis. The study is a part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF in patients with idiopathic pulmonary fibrosis and FIBRONEER-ILD in adults with other progressive fibrosing interstitial lung diseases (ILDs).
• In September 2022, Bellerophon Therapeutics, Inc. announced that the FDA accepted the trial size reduction application for its current REBUILD Phase 3 registration trial of INOpulse, indicated for the treatment of fibrotic interstitial lung disease (LD). 
• In May 2022, ArisGlobal, a global leader in drug safety solutions, acquired Boehringer Ingelheim's BRASS digital innovation. The acquisition enabled the former to enhance its LifeSphere technology platform by integrating BRASS into LifeSphere Clarity. This integration has contributed to the advancement of pharmacovigilance and patient safety across the industry. Moreover, ArisGlobal has expanded its clinical diagnostics business presence in various regions worldwide, consolidating its global position.
• In March 2022, Bristol Myers Squibb, a leading pharmaceutical company, announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition has significantly strengthened Bristol Myers Squibb's global presence in the pharmaceutical market, allowing it to be more proactive in bringing innovations to the industry while expanding its portfolio of life-saving therapies and treatments.